Desferrioxamine-induced Ototoxicity (SNHL) in β-Thalassaemia

Authors

  • C. Pandu Varaprasad Department of Pharmacy Practice, P. Rami Reddy College of Pharmacy, Kadapa, A.P., India
  • Nrithya S. Kumar Department of Pharmacy Practice, P. Rami Reddy College of Pharmacy, Kadapa, A.P., India
  • Anakha Thyag Department of Pharmacy Practice, P. Rami Reddy College of Pharmacy, Kadapa, A.P., India
  • M. Venkata Subbaiah Department of Pharmacy Practice, P. Rami Reddy College of Pharmacy, Kadapa, A.P., India

Abstract

 

Thalassaemia is a hereditary disorder requiring regular blood transfusion. The repeated transfusion results in an iron overload state with succeeding complications. Iron chelation therapy with desferrioxamine removes excess iron and its prolonged usage causes ototoxicity.

This is a rare disease observed in the ENT (OP) Department, Rajiv Gandhi Institute of Medical Sciences (RIMS) [a 750 bedded tertiary teaching hospital], Kadapa, AP, India. A 12-year-old female patient was presented with complains of hearing loss (left ear) starting two months ago, associated with itching. On past medication history, he was a known thalassaemia patient since seven years and on regular medication with desferrioxamine (500 mg). The diagnosis was confirmed by Rinne test, Weber test and Air Bone Conduction (ABC) test. So it was confirmed that desferrioxamine induced ototoxicity and was reported as an adverse drug reaction (ADR). Based upon the Naranjo’s scale, the assessment was found to be as probable ADR (Causality assessment score equal to +7). The patients with β-Thalassaemia receiving chelating agent need to be followed up for regular audiological monitoring to detect any early changes in the hearing. Both the clinical pharmacist and the audiologist play a critical role in the process of ototoxic monitoring.

 

Keywords: β-Thalassaemia, desferrioxamine, ototoxicity, chelating agent, hearing loss

Cite this Article

Varaprasad CP, Kumar NS, Thyag A, et al. Desferrioxamine-induced Ototoxicity (SNHL) in β-Thalassaemia. Research & Reviews: A Journal of Pharmacology. 2016; 6(1): 10–12p.

Downloads

Published

2019-07-23

Issue

Vol. 6 No. 1 (2016)

Section

Case Study

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.